Novel lecithin: cholesterol acyltransferase-based therapeutic approaches

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Genetics

Background:

• Lecithin:cholesterol acyltransferase (LCAT) plays a crucial role in high-density lipoprotein (HDL) metabolism.
• Dysfunctional LCAT activity is implicated in familial LCAT deficiency (FLD) and contributes to cardiovascular disease.
• Novel therapeutic strategies targeting LCAT are being explored to address these conditions.

Purpose of the Study:

• To review recent advancements in lecithin:cholesterol acyltransferase (LCAT)-based therapeutic approaches.
• To evaluate LCAT-based therapies for atherosclerosis, acute coronary syndrome, and LCAT deficiency disorders.

Main Methods:

• Review of recent preclinical and clinical trial data on LCAT-based therapies.
• Analysis of enzyme replacement therapy, gene therapy, engineered cell therapies, and small molecule activators.
• Consideration of lifestyle modifications for managing LCAT deficiency.

Main Results:

• Enzyme replacement therapy with recombinant human LCAT is clinically advanced, with completed Phase I and 2A trials.
• Liver-directed LCAT gene therapy and engineered cell therapies represent promising alternative approaches.
• Peptide and small molecule LCAT activators have demonstrated efficacy in early preclinical studies.
• Lifestyle modifications may help manage FLD but require further investigation.

Conclusions:

• Novel LCAT therapies demonstrate potential as HDL-raising agents.
• These therapies may be beneficial for treating familial LCAT deficiency (FLD).
• LCAT-based treatments could also be applicable to atherosclerosis and other disorders characterized by low or dysfunctional HDL.